Oxford Cannabinoid Technologies Holdings plc (OCTP) ORD GBP0.001
Oxford Cannabinoid Technologies Holdings plc is a United Kingdom-based pharmaceutical company developing prescription cannabinoid medicines. The Company is working with three types of cannabinoid compounds: synthesized phytocannabinoids, cannabinoid derivatives and novel chemical entities. Its drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and other therapeutic areas. It has a portfolio of four drug development programs: Program 1 (OCT461201), Program 2 (OCT130401), Program 3 (Cannabinoid derivative) and Program 4 (Cannabinoid derivative). Its OCT461201 is a new chemical entity, CB2 receptor agonist, chemically synthesized to behave like a cannabinoid. Its OCT130401 is a drug/device combination. It has a portfolio of over 500 derivatives and intellectual property rights, including 14 patent families and associated research data.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.